"Fingolimod Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.
| Descriptor ID |
D000068876
|
| MeSH Number(s) |
D02.033.100.700.350 D02.033.455.706.431 D02.092.063.700.350
|
| Concept/Terms |
Fingolimod Hydrochloride- Fingolimod Hydrochloride
- Hydrochloride, Fingolimod
- 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Fingolimod Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Fingolimod Hydrochloride".
This graph shows the total number of publications written about "Fingolimod Hydrochloride" by people in this website by year, and whether "Fingolimod Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fingolimod Hydrochloride" by people in Profiles.
-
Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Hass S, Thangavelu K, Leist TP. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis. Mult Scler Relat Disord. 2016 Nov; 10:204-212.
-
Rosini JM, Rajasimhan S, Fellows SE, Nomura JT. Delayed cardiac dysrhythmias after fingolimod administration. Am J Emerg Med. 2015 Jul; 33(7):987.e1-3.
-
Huggins A, Sergott RC. Gilenya safety update: cardiac and macula. Curr Opin Ophthalmol. 2012 Nov; 23(6):457-9.
-
Huggins A, Sergott RC. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety. Curr Opin Ophthalmol. 2011 Nov; 22(6):447-50.